Recent Finacing
Recent Raise
Protagonist Therapeutics develops orally stable, GI-restricted peptide drugs using a platform combining computational design, phage display, and peptide chemistry, advancing PTG-100, an alpha-4-beta-7-targeted therapy for IBD.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
